KRAS Mutation in Colon Cancer: A Marker of Resistance to EGFR-I Therapy

摘要: Introduction and Design The introduction of the epidermal growth factor receptor inhibitors (EGFR-I) has increased treatment options available for patients with metastatic colorectal cancer (mCRC). Two EGFR-I agents currently approved mCRC are fully human monoclonal antibody panitumumab mouse-human chimeric cetuximab. While these have demonstrated activity across multiple lines therapy, early studies suggested that clinical benefit was confined to a subset treated. Mutation KRAS oncogene emerged as powerful negative predictive biomarker identify who do not from therapy. Multiple retrospective analyses is limited tumors harboring wild-type gene. In this review, pathway evaluating prognostic marker in CRC discussed along advances gene mutation testing. Clinical trials role status response monotherapy or combination chemotherapy also highlighted ongoing on curative resections rates.